Mary K. Brainerd
Known title: DirectorCIK: 0001195918
Mary K. Brainerd's purchase track record
Mary K. Brainerd has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/22/2022 | SYK | $4K | +15.7% | +21.7% | +3.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SYK | ▲ Buy | Grant | 762 | $0 | 5/6/2026 | View on chart |
| SYK | ▲ Buy | Grant | 560 | $0 | 5/8/2025 | View on chart |
| SYK | ▲ Buy | Grant | 653 | $0 | 5/9/2024 | View on chart |
| SYK | ▲ Buy | Grant | 705 | $0 | 5/10/2023 | View on chart |
| SYK | ▲ Buy | Option Exercise | 841 | $0 | 5/4/2023 | View on chart |
| SYK | ▲ Buy | Open Market | 18 | $4K | 11/22/2022 | View on chart |
| SYK | ▲ Buy | Option Exercise | 693 | $0 | 5/4/2022 | View on chart |
| SYK | ▲ Buy | Open Market | 3 | $557 | 6/12/2020 | View on chart |
| SYK | ▲ Buy | Open Market | 36 | $7K | 5/12/2020 | View on chart |
| SYK | ▲ Buy | Open Market | 11 | $2K | 9/12/2019 | View on chart |
| SYK | ▲ Buy | Open Market | 63 | $13K | 6/26/2019 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3
Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3. Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.